- Conditions
- Graft Rejection
- Interventions
- Alemtuzumab, Anti-Thymocyte Globulin
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- PEGPH20, Nab-paclitaxel, Gemcitabine, Dexamethasone, Enoxaparin
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more
- Conditions
- Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm, Heparin-induced Thrombocytopenia Type II
- Interventions
- Continuous Low-Dose IV Unfractionated Heparin Infusion
- Drug
- Lead sponsor
- Robert F. James
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more